最新研究进展 -MedSci.cn 相关研究进展 -MedSci.cn

文献资料信息综合查询系统

筛选条件 共查询到125条结果

排序方式

文献标题

第一作者

所属期刊

影响指数

~

重置筛选

Separate and combined effect of visit-to-visit glycaemic variability and mean fasting blood glucose level on all-cause mortality in patients with type 2 diabetes: A population-based cohort study

期刊： DIABETES OBESITY & METABOLISM, 2022; 24 (12)

Aims To assess the independent and combined impacts of visit-to-visit fasting blood glucose variability (VVV-FBG) and mean fasting blood glucose level......

Efficacy and safety of a basal insulin+2-3 oral antihyperglycaemic drugs regimen versus a twice-daily premixed insulin plus metformin regimen after short-term intensive insulin therapy in individuals with type 2 diabetes: The multicentre, open-label, randomized controlled BEYOND-V trial

期刊： DIABETES OBESITY & METABOLISM, 2022; 24 (10)

Aim To compare the efficacy and safety of basal insulin glargine 100 units/ml (Gla) + 2-3 oral antihyperglycaemic drugs (OADs) with twice-daily premix......

The missing heritability in type 1 diabetes

期刊： DIABETES OBESITY & METABOLISM, 2022; 24 (10)

Type 1 diabetes (T1D) is a complex autoimmune disease characterized by an absolute deficiency of insulin. It affects more than 20 million people world......

Cardiorenal benefits of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes without cardiovascular and renal diseases

期刊： DIABETES OBESITY & METABOLISM, 2022; 24 (3)

Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta-analysis

期刊： DIABETES OBESITY & METABOLISM, 2022; 24 (8)

Aims To conduct a systematic review and network meta-analysis to determine the comparative effectiveness of sodium-glucose cotransporter-2 (SGLT2) inh......

Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis

期刊： DIABETES OBESITY & METABOLISM, 2022; 24 (11)

Aims To compare the efficacy of sodium-glucose cotransporter-2 (SGLT2) inhibitors, nonsteroidal mineralocorticoid receptor antagonists (MRAs), selecti......

Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan-L-CN randomized controlled trial

期刊： DIABETES OBESITY & METABOLISM, 2022; 24 (11)

Aims To evaluate the efficacy and safety of iGlarLixi compared with iGlar in Chinese adults with type 2 diabetes advancing therapy from basal insulin ......

Immunogenicity of LY2963016 insulin glargine and Lantus (R) insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus

期刊： DIABETES OBESITY & METABOLISM, 2022; 24 (6)

Aims To evaluate the immunogenicity of LY2963016 insulin glargine (LY IGlar) versus originator insulin glargine (IGlar [Lantus (R)]) in Chinese patien......

Serum bile acid response to oral glucose is attenuated in patients with early type 2 diabetes and correlates with 2-hour plasma glucose in individuals without diabetes

期刊： DIABETES OBESITY & METABOLISM, 2022; 24 (6)

Aim To determine the serum bile acid (BA) response to 75-g oral glucose in individuals without diabetes, and whether this is attenuated in patients wi......

Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: A randomized, open-label, noninferiority trial

期刊： DIABETES OBESITY & METABOLISM, 2022; 24 (2)

Objectives To determine the safety and efficacy of canagliflozin in comparison to metformin in polycystic ovary syndrome (PCOS) patients with insulin ......

Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomized, open-label, prospective study (ACADEMIC)

期刊： DIABETES OBESITY & METABOLISM, 2022; 24 (6)

Aims To demonstrate the noninferiority of alogliptin to acarbose, in terms of antidiabetic efficacy, in Chinese people with uncontrolled type 2 diabet......

Cholecystectomy is associated with dysglycaemia: Cross-sectional and prospective analyses

期刊： DIABETES OBESITY & METABOLISM, 2022; 24 (8)

Cholecystectomy has been reported to be associated with increased risk of diabetes in cross-sectional studies. In the current study, we performed both......

Once-weekly semaglutide for obesity or overweight: A systematic review and meta-analysis

期刊： DIABETES OBESITY & METABOLISM, 2022; 24 (4)

Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial

期刊： DIABETES OBESITY & METABOLISM, 2022; 24 (8)

Aims To compare the efficacy and safety of iGlarLixi with insulin glargine 100 units/mL (iGlar) and lixisenatide (Lixi), in Asian Pacific people with ......

Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes: A 24-week, multi-centre, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial

期刊： DIABETES OBESITY & METABOLISM, 2022; 24 (11)

Aim To evaluate the efficacy and safety of DBPR108 (prusogliptin), a novel dipeptidyl peptidase-4 (DPP-4) inhibitor, as an add-on therapy in patients ......

科室
- - 订阅+
  - 更多科室
工具
服务